Abstract
This study compared the safety and efficacy of cilostazol and clopidogrel after coronary stenting. Patients (n = 689) who underwent successful stenting were randomly assigned to receive cilostazol (group 1, n = 344, 612 lesions) or clopidogrel (group 2, n = 345, 628 lesions). The incidence of subacute stent thrombosis or major adverse cardiac events, including death, myocardial infarction, and target lesion revascularization within 30 days (2.6% in group 1 vs 2.0% in group 2, p = 0.61) and side effects that required cessation of study drug (0.6% each) did not differ statistically between groups. These results indicate that cilostazol is as safe and effective as clopidogrel in preventing thrombotic complications after stenting.
Publication types
-
Clinical Trial
-
Comparative Study
-
Randomized Controlled Trial
MeSH terms
-
Aged
-
Angioplasty, Balloon, Coronary / adverse effects*
-
Aspirin / therapeutic use
-
Cilostazol
-
Clopidogrel
-
Coronary Restenosis / etiology
-
Coronary Restenosis / prevention & control*
-
Female
-
Humans
-
Male
-
Middle Aged
-
Myocardial Infarction / etiology
-
Myocardial Infarction / prevention & control
-
Platelet Aggregation Inhibitors / therapeutic use*
-
Prospective Studies
-
Stents / adverse effects*
-
Tetrazoles / therapeutic use*
-
Thrombosis / etiology
-
Thrombosis / prevention & control
-
Ticlopidine / analogs & derivatives*
-
Ticlopidine / therapeutic use*
-
Treatment Outcome
Substances
-
Platelet Aggregation Inhibitors
-
Tetrazoles
-
Clopidogrel
-
Cilostazol
-
Ticlopidine
-
Aspirin